Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 10/20 | 0.42 |
| ▸ | NPY1R | P25929 | 5/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557532 | 0.83 | REN (0.49) | CTSK | |
| SCHEMBL5552333 | 0.81 | PPID (0.40) | NPY4RNPY1RNPY2RNPY5RERAP2 | |
| SCHEMBL3237580 | 0.79 | HTR1A (0.48) | HTR1ADRD2 | |
| SCHEMBL5685768 | 0.76 | CTSK (0.53) | CTSKANPEP | |
| SCHEMBL5685770 | 0.76 | EPHX2 (0.48) | CTSKANPEP | |
| SCHEMBL27569901 | 0.76 | CTSK (0.53) | CTSKANPEP | |
| SCHEMBL5557666 | 0.76 | ERAP2 (0.49) | NPY4RNPY1RNPY2RNPY5RANPEP | |
| SCHEMBL28556186 | 0.72 | DPP4 (0.58) | NPY4RNPY1RNPY2RNPY5RERAP2 | |
| SCHEMBL19982696 | 0.69 | ERAP2 (0.65) | ANPEPERAP2ERAP1LNPEP | |
| SCHEMBL19002484 | 0.69 | CYP3A4 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | NPY4R 4772/4885NPY1R 4549/4885NPY2R 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.